Zacks: Brokerages Expect Omeros Co. (NASDAQ:OMER) Will Post Earnings of -$0.38 Per Share

Brokerages expect Omeros Co. (NASDAQ:OMER) to post ($0.38) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Omeros’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.47). Omeros reported earnings per share of ($0.60) in the same quarter last year, which suggests a positive year-over-year growth rate of 36.7%. The company is expected to issue its next quarterly earnings results on Thursday, August 8th.

According to Zacks, analysts expect that Omeros will report full-year earnings of ($1.51) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($0.68). For the next fiscal year, analysts expect that the business will report earnings of ($0.86) per share, with EPS estimates ranging from ($2.13) to $1.13. Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Omeros.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.04). The company had revenue of $21.80 million for the quarter, compared to the consensus estimate of $23.18 million. During the same period in the prior year, the company earned ($0.62) EPS. The firm’s revenue was up 1271.1% compared to the same quarter last year.



OMER has been the topic of a number of research analyst reports. BidaskClub cut shares of Omeros from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 11th. HC Wainwright set a $35.00 price objective on shares of Omeros and gave the stock a “buy” rating in a report on Tuesday, May 28th. Wedbush reissued a “hold” rating and set a $18.00 price objective on shares of Omeros in a report on Monday, May 20th. Zacks Investment Research cut shares of Omeros from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Finally, ValuEngine cut shares of Omeros from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. Omeros currently has a consensus rating of “Buy” and a consensus target price of $26.50.

A number of hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its holdings in Omeros by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 214,955 shares of the biopharmaceutical company’s stock worth $2,394,000 after purchasing an additional 817 shares in the last quarter. Legal & General Group Plc raised its holdings in Omeros by 12.7% during the fourth quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 945 shares in the last quarter. Keeley Teton Advisors LLC raised its holdings in Omeros by 8.9% during the fourth quarter. Keeley Teton Advisors LLC now owns 13,001 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 1,060 shares in the last quarter. Rocky Mountain Advisers LLC raised its holdings in Omeros by 19.2% during the first quarter. Rocky Mountain Advisers LLC now owns 15,210 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 2,450 shares in the last quarter. Finally, National Asset Management Inc. raised its holdings in Omeros by 19.7% during the fourth quarter. National Asset Management Inc. now owns 15,180 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 2,500 shares in the last quarter. 52.12% of the stock is currently owned by institutional investors.

Omeros stock traded down $0.29 during trading on Tuesday, reaching $16.09. The stock had a trading volume of 11,634 shares, compared to its average volume of 329,518. Omeros has a 52-week low of $10.30 and a 52-week high of $27.00. The firm has a 50 day moving average of $17.77. The stock has a market capitalization of $794.77 million, a PE ratio of -7.24 and a beta of 3.40.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Recommended Story: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.